PMA device
Dexcom G4 Platinum Contiuous Glucose Monitoring System
Dexcom, Inc. · Sensor, Glucose, Invasive, Non-Adjunctive (PQF, Class III) · First FDA decision May 22, 2017, newest May 22, 2017Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
0
Naming "G4 Platinum Contiuous"
MAUDE reports
1
Brand "G4 Platinum Contiuous", since 2015
PubMed studies
0
Mentioning "G4 Platinum Contiuous"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom G4 Platinum Contiuous Glucose Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DEXCOM G4 PLATINUM CONTIUOUS GLUCOSE MONITORING SYSTEMPMA supplement
P120005-S059 · Decided May 22, 2017 · 123 days after receipt · Normal 180 Day Track No User Fee
Device type: Sensor, glucose, invasive, non-adjunctive (PQF) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "G4 Platinum Contiuous", any status and sponsor, newest update first.
No registered device study names "G4 Platinum Contiuous".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "G4 Platinum Contiuous", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code PQF
328,575 reports: 326,235 malfunction, 2,330 injury, 10 death
Newest reports for this brand
3004753838-2015-66099 · Received Oct 30, 2015 · Event dated Oct 1, 2015
Device type: Sensor, Glucose, Invasive (MDS)
Device problem as coded: Device Operates Differently Than Expected
Patient problem as coded: No Consequences Or Impact To Patient
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1560-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive (MDS)
Z-1561-2020 · Started Feb 3, 2020
Reason given: The company identified potential interference from hydroxyurea. Patient use of the anti-neoplastic drug may falsely elevate glucose readings on the Continuous Glucose Monitoring Systems.
Cause as FDA categorized it: Under Investigation by firm · Device type: Sensor, Glucose, Invasive, Non-Adjunctive (PQF)
Published research
The most relevant PubMed records for "G4 Platinum Contiuous"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PQF.
- Dexcom G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2019
- Simplera SystemMedtronic Minimed · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.